(Q41757845)

8 October 2017

1 reference

title

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity (English)

1 reference

8 October 2017

1 reference

1 reference

3

1 reference

8 October 2017

van Ede AE

1

1 reference

8 October 2017

Laan RF

series ordinal

2

1 reference

8 October 2017

De Abreu RA

series ordinal

4

1 reference

8 October 2017

van de Putte LB

series ordinal

5

1 reference

8 October 2017

publication date

1 April 1998

1 reference

Seminars in Arthritis and Rheumatism

8 October 2017

published in

1 reference

8 October 2017

volume

27

1 reference

8 October 2017

issue

5

1 reference

8 October 2017

page(s)

277-292

1 reference

Methotrexate and rheumatoid arthritis

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Long-term methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate in rheumatoid arthritis. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Sulfonamides and folic acid antagonists: a historical review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The cellular pharmacology of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Alteration of purine metabolism by AICA-riboside in human B lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The total serum homocysteine as an indicator of vitamin B12 and folate status

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Homocysteinemia due to folate deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methionine metabolism in mammals

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

S-adenosylmethionine decarboxylase: a brief review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

1 reference

7 January 2021

Polyamine biosynthesis is necessary for interleukin-2-dependent proliferation but not for interleukin-2 production or high-affinity interleukin-2 receptor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Intracellular polyamine biosynthesis is required for interleukin 2 responsiveness during lymphocyte mitogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Polyglutamation of methotrexate. Is methotrexate a prodrug?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Polygammaglutamyl metabolites of methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Accumulation of methotrexate diglutamate in human liver during methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight–week randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate treatment of rheumatoid arthritis: effects on radiological progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The relative toxicity of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate--the relationship between dose and clinical effect

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate: mechanism of action in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Antiproliferative effects of methotrexate on peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Immunologic studies of rheumatoid arthritis patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate therapy in rheumatoid arthritis. Current status

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Molecular mechanism of methotrexate action in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Molecular therapeutics. Methotrexate and its mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

1 reference

7 January 2021

Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methylacetylenic putrescine (MAP), an inhibitor of polyamine biosynthesis, prevents the development of collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Cellular immunodeficiency associated with nucleoside phosphorylase deficiency. Immunologic and biochemical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside phosphorylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Lymphocyte purine 5'-nucleotidase edficiency in primary hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Lymphocyte Ecto-5′-Nucleotidase Deficiency in Agammaglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Infections during low-dose methotrexate treatment in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Long-term second-line treatment: a prospective drug survival study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Management of adverse effects of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Risk factors of second-line antirheumatic drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate Accumulation and Folate Depletion in Cells as a Possible Mechanism of Chronic Toxicity to the Drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Biological effects of folic acid antagonists with antineoplastic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Abnormal homocysteine metabolism in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate and trimethoprim-sulphamethoxazole--a potentially hazardous combination.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Antineoplastic agents. Drug interactions of clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The effect of organic acids on renal clearance of methotrexate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Combination chemotherapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Rational disease-modifying anti-rheumatic drug (DMARD) therapy: is it possible?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Folate supplementation and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

A patient with nucleoside phosphorylase deficiency, selective T-cell deficiency, and autoimmune hemolytic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

Mechanism of action of hydroxychloroquine as an antirheumatic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2898%2980049-8

7 January 2021

10.1016/S0049-0172(98)80049-8

Identifiers

DOI

1 reference

8 October 2017

1 reference